Abstract
Objective: To evaluate the benefits and harms of low dose aspirin in people with diabetes and no cardiovascular disease. Design: Meta-analysis of randomised controlled trials. Data sources: Medline (1966-November 2008), the Cochrane central register of controlled trials (Cochrane Library 2008;issue 4), and reference lists of retrieved articles. Review methods: Randomised trials of aspirin compared with placebo or no aspirin in people with diabetes and no pre-existing cardiovascular disease were eligible for inclusion. Data on major cardiovascular events (death from cardiovascular causes, non-fatal myocardial infarction, non-fatal stroke, and all cause mortality) were extracted and pooled with a random effect model. Results are reported as relative risks with 95% confidence intervals. Results: Of 157 studies in the literature searches, six were eligible (10 117 participants). When aspirin was compared with placebo there was no statistically significant reduction in the risk of major cardiovascular events (five studies, 9584 participants; relative risk 0.90, 95% confidence interval 0.81 to 1.00), cardiovascular mortality (four studies, n=8557, 0.94; 0.72 to 1.23), or all cause mortality (four studies, n=8557; 0.93, 0.82 to 1.05). Significant heterogeneity was found in the analysis for myocardial infarction (I2=62.2%; P=0.02) and stroke (I 2=52.5%; P=0.08). Aspirin significantly reduced the risk of myocardial infarction in men (0.57, 0.34 to 0.94) but not in women (1.08, 0.71 to 1.65; P for interaction=0.056). Evidence relating to harms was inconsistent. Conclusions: A clear benefit of aspirin in the primary prevention of major cardiovascular events in people with diabetes remains unproved. Sex may be an important effect modifier. Toxicity is to be explored further.
| Original language | English |
|---|---|
| Pages (from-to) | 1238 |
| Number of pages | 1 |
| Journal | British Medical Journal |
| Volume | 339 |
| Issue number | 7732 |
| DOIs | |
| Publication status | Published - 2009 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Aspirin for primary prevention of cardiovascular events in people with diabetes : Meta-analysis of randomised controlled trials. / De Berardis, Giorgia; Sacco, Michele; Strippoli, Giovanni F M; Pellegrini, Fabio; Graziano, Giusi; Tognoni, Gianni; Nicolucci, Antonio.
In: British Medical Journal, Vol. 339, No. 7732, 2009, p. 1238.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Aspirin for primary prevention of cardiovascular events in people with diabetes
T2 - Meta-analysis of randomised controlled trials
AU - De Berardis, Giorgia
AU - Sacco, Michele
AU - Strippoli, Giovanni F M
AU - Pellegrini, Fabio
AU - Graziano, Giusi
AU - Tognoni, Gianni
AU - Nicolucci, Antonio
PY - 2009
Y1 - 2009
N2 - Objective: To evaluate the benefits and harms of low dose aspirin in people with diabetes and no cardiovascular disease. Design: Meta-analysis of randomised controlled trials. Data sources: Medline (1966-November 2008), the Cochrane central register of controlled trials (Cochrane Library 2008;issue 4), and reference lists of retrieved articles. Review methods: Randomised trials of aspirin compared with placebo or no aspirin in people with diabetes and no pre-existing cardiovascular disease were eligible for inclusion. Data on major cardiovascular events (death from cardiovascular causes, non-fatal myocardial infarction, non-fatal stroke, and all cause mortality) were extracted and pooled with a random effect model. Results are reported as relative risks with 95% confidence intervals. Results: Of 157 studies in the literature searches, six were eligible (10 117 participants). When aspirin was compared with placebo there was no statistically significant reduction in the risk of major cardiovascular events (five studies, 9584 participants; relative risk 0.90, 95% confidence interval 0.81 to 1.00), cardiovascular mortality (four studies, n=8557, 0.94; 0.72 to 1.23), or all cause mortality (four studies, n=8557; 0.93, 0.82 to 1.05). Significant heterogeneity was found in the analysis for myocardial infarction (I2=62.2%; P=0.02) and stroke (I 2=52.5%; P=0.08). Aspirin significantly reduced the risk of myocardial infarction in men (0.57, 0.34 to 0.94) but not in women (1.08, 0.71 to 1.65; P for interaction=0.056). Evidence relating to harms was inconsistent. Conclusions: A clear benefit of aspirin in the primary prevention of major cardiovascular events in people with diabetes remains unproved. Sex may be an important effect modifier. Toxicity is to be explored further.
AB - Objective: To evaluate the benefits and harms of low dose aspirin in people with diabetes and no cardiovascular disease. Design: Meta-analysis of randomised controlled trials. Data sources: Medline (1966-November 2008), the Cochrane central register of controlled trials (Cochrane Library 2008;issue 4), and reference lists of retrieved articles. Review methods: Randomised trials of aspirin compared with placebo or no aspirin in people with diabetes and no pre-existing cardiovascular disease were eligible for inclusion. Data on major cardiovascular events (death from cardiovascular causes, non-fatal myocardial infarction, non-fatal stroke, and all cause mortality) were extracted and pooled with a random effect model. Results are reported as relative risks with 95% confidence intervals. Results: Of 157 studies in the literature searches, six were eligible (10 117 participants). When aspirin was compared with placebo there was no statistically significant reduction in the risk of major cardiovascular events (five studies, 9584 participants; relative risk 0.90, 95% confidence interval 0.81 to 1.00), cardiovascular mortality (four studies, n=8557, 0.94; 0.72 to 1.23), or all cause mortality (four studies, n=8557; 0.93, 0.82 to 1.05). Significant heterogeneity was found in the analysis for myocardial infarction (I2=62.2%; P=0.02) and stroke (I 2=52.5%; P=0.08). Aspirin significantly reduced the risk of myocardial infarction in men (0.57, 0.34 to 0.94) but not in women (1.08, 0.71 to 1.65; P for interaction=0.056). Evidence relating to harms was inconsistent. Conclusions: A clear benefit of aspirin in the primary prevention of major cardiovascular events in people with diabetes remains unproved. Sex may be an important effect modifier. Toxicity is to be explored further.
UR - http://www.scopus.com/inward/record.url?scp=71749105108&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=71749105108&partnerID=8YFLogxK
U2 - 10.1136/bmj.b4531
DO - 10.1136/bmj.b4531
M3 - Article
VL - 339
SP - 1238
JO - British Medical Journal
JF - British Medical Journal
SN - 0959-8146
IS - 7732
ER -